Clinical Trial Update: Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the JAK inhibitor tofacitinib for prevention of photosensitivity in cutaneous lupus has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Lupus Erythematosus

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Cutaneous Lupus | Phase 1 | Status: COMPLETED | Results posted: 2025-03-21